oral, insurmountable, selective CCR6 antagonist Ph. I in HV completed, in Ph. I for ulcerative colitis from directed screening for novel negative allosteric modulators J. Pharm. Exp. Ther., May 4, 2023 Pfizer, Cambridge, MA